Abstract
The role of adjuvant chemotherapy in the treatment of breast cancer has been the subject of intense research activity in recent years. It is now generally accepted that some types of adjuvant therapy have a positive effect on disease-free and overall survival, but the effect size appears to be modest and the optimal type of adjuvant therapy for different groups of patients remains unclear. One major study of adjuvant therapy in breast cancer patients that generated considerable interest and controversy was an intergroup trial of the value of increasing the dose of doxorubicin or adding paclitaxel (Taxol®) to standard chemotherapy. The design was a 3 x 2 factorial design (three different doses of doxorubicin with and without paclitaxel). Based on the results of the first planned interim analysis suggesting improved disease-free and overall survival in patients receiving paclitaxel, the DSMB released the results to the study team. The events and considerations leading to the decision to release the results and some of the subsequent controversies that arose in the medical community because of this decision are discussed in this paper.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Piccart M. 2003. The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Research and Treatment 79:S25–S34.
Cardoso F, Lohrisch C, Piccart MJ. 2003. Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer. Drugs of Today 39:399–414.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. 2003. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983.
O’Brien PC, Fleming TR. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549–556.
George SL, Freidlin B, Korn EL. 2004. Strength of accumulating evidence and data monitoring committee decision making. Stat Med 23:2659–2672.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, et al. 1998. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc ASCO 17:390a.
Qian J, Stangl DK, George SL. A Weibull model for survival data: Using prediction to decide when to stop a clinical trial. 1996 In Berry DA, Stangl DK (eds.): Bayesian Biostatistics, pp. 187–205. Marcel Dekker, New York.
Piccart MJ, Lohrisch C, Duchateau L, Buyse M. 2001. Taxanes in the adjuvant treatment of breast cancer: Why not yet? J Natl Cancer Inst Monogr 30:88–95.
Freidlin B, Korn EL, George SL. 1999. Data monitoring committees and interim monitoring guidelines. Control ClinTrials 20:395–407.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
George, S.L., Green, M.R. (2006). Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_34
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_34
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)